Ticker

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE - Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 27th, there was short interest totaling 538,588 shares, an increase of 1,973.5% from the February 12th total of 25,975 shares. Currently, 55.6% of the shares of the company are

BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on February 19, 2026, Sensei's Board of Directors granted 17 new employees, in the aggregate, options to purchase 2,319,893 shares of the Company's common stock in connection with their employment, including a grant to Anand Parikh of an option to purchase 1,239,305 shares of the Company's common stock in connection…

SNSE up on acquisition of Faeth Therapeutics, $200M private placement, and addition of PIKTOR to pipeline targeting cancer.

BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has acquired Faeth Therapeutics Inc. (“Faeth”), a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. The acquisition brings Faeth's lead asset PIKTOR, a proprietary investigational all-oral combination of serabelisib and sapanisertib that inhibits multiple nodes…

Cynata Therapeutics (OTCMKTS:CYYNF - Get Free Report) and Sensei Biotherapeutics (NASDAQ: SNSE - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends. Analyst Recommendations This is a summary of